Breaking: Is Buying Stock Like EXACT Sciences Corporation After Such Increase Winning Strategy?

Breaking: Is Buying Stock Like EXACT Sciences Corporation After Such Increase Winning Strategy?

The stock of EXACT Sciences Corporation (NASDAQ:EXAS) is a huge mover today! About 2.75M shares traded hands or 10.89% up from the average. EXACT Sciences Corporation (NASDAQ:EXAS) has risen 210.18% since February 26, 2016 and is uptrending. It has outperformed by 199.75% the S&P500.
The move comes after 9 months positive chart setup for the $1.85B company. It was reported on Sep, 30 by Barchart.com. We have $27.81 PT which if reached, will make NASDAQ:EXAS worth $925.00M more.

Analysts await EXACT Sciences Corporation (NASDAQ:EXAS) to report earnings on November, 3. They expect $-0.44 earnings per share, up 2.22% or $0.01 from last year’s $-0.45 per share. After $-0.46 actual earnings per share reported by EXACT Sciences Corporation for the previous quarter, Wall Street now forecasts -4.35% EPS growth.

EXACT Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Out of 13 analysts covering EXACT Sciences (NASDAQ:EXAS), 5 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 38% are positive. EXACT Sciences has been the topic of 25 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Mizuho maintained EXACT Sciences Corporation (NASDAQ:EXAS) on Wednesday, October 7 with “Buy” rating. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Lake Street on Friday, July 24. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) has “Equal-Weight” rating given on Thursday, February 25 by Stephens. The stock has “Buy” rating given by Canaccord Genuity on Monday, August 24. Craig Hallum initiated the shares of EXAS in a report on Thursday, October 1 with “Buy” rating. As per Friday, October 30, the company rating was maintained by TH Capital. The stock has “Buy” rating given by Canaccord Genuity on Wednesday, October 7. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned “Neutral” rating by Roth Capital on Thursday, February 25. Lake Street maintained it with “Hold” rating and $7 target price in Tuesday, November 24 report. The firm has “Buy” rating given on Thursday, February 25 by Jefferies.

According to Zacks Investment Research, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.”

Insitutional Activity: The institutional sentiment increased to 1.42 in 2016 Q2. Its up 0.70, from 0.72 in 2016Q1. The ratio is positive, as 18 funds sold all EXACT Sciences Corporation shares owned while 41 reduced positions. 30 funds bought stakes while 54 increased positions. They now own 87.89 million shares or 11.45% more from 78.86 million shares in 2016Q1.
The Florida-based Raymond James Advsrs has invested 0% in EXACT Sciences Corporation (NASDAQ:EXAS). Moreover, Bnp Paribas Arbitrage Sa has 0% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 3,910 shares. State Bank Of Montreal Can accumulated 16,758 shares or 0% of the stock. The New York-based Blackrock Inc has invested 0% in EXACT Sciences Corporation (NASDAQ:EXAS). Guggenheim Lc has 0.01% invested in the company for 160,302 shares. Everpoint Asset Management Limited Liability Company has 0.58% invested in the company for 2.38M shares. Cam Group Incorporated Hldg A S has 0.06% invested in the company for 250,000 shares. Orbimed Advsrs Ltd Liability Corporation has 2.13M shares for 0.27% of their US portfolio. Sandy Spring Natl Bank accumulated 0% or 3,500 shares. Massmutual Tru Fsb Adv holds 0% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS) for 10,000 shares. Quantitative Invest Mngmt Limited Liability Company last reported 127,000 shares in the company. Massachusetts Fincl Svcs Ma reported 449,506 shares or 0% of all its holdings. Moreover, Ifc Fl has 0.03% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 23,400 shares. The Illinois-based Columbia Wanger Asset Ltd Llc has invested 0.11% in EXACT Sciences Corporation (NASDAQ:EXAS). Commonwealth Financial Svcs has 0.01% invested in the company for 500 shares.

Insider Transactions: Since July 25, 2016, the stock had 2 insider buys, and 2 selling transactions for $67,363 net activity. Shares for $109,416 were sold by LIDGARD GRAHAM PETER. Sterling Lionel bought $90,500 worth of stock. Zanotti Katherine S bought $60,613 worth of stock or 3,380 shares. ARORA MANEESH sold 7,359 shares worth $109,060.

Another recent and important EXACT Sciences Corporation (NASDAQ:EXAS) news was published by Prnewswire.com which published an article titled: “Exact Sciences to host third-quarter 2016 results webcast and call” on September 28, 2016.

EXAS Company Profile

Exact Sciences Corporation, incorporated on February 10, 1995, is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. The Firm has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The Company’s Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test (FIT). The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment